Theseus Pharmaceuticals Inc

NASDAQ:THRX  
15.92
+0.28 (+1.79%)
Earnings Announcements

Theseus Pharmaceuticals Announces Business And Program Highlights And Reports Third Quarter 2021 Financial Results

Published: 11/15/2021 12:24 GMT
Theseus Pharmaceuticals Inc (THRX) - Theseus Pharmaceuticals Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results.
Q3 Loss per Share $5.16.
Initiation of Phase 1/2 Clinical Trial for The-630 Expected Between Late Q4 2021 and Mid-q1 2022.
Expects Cash, Cash Equivalents, Including Proceeds From Ipo, to Fund Operations and Capital Expenditures Into H2 2024.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.21

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.30

More details on our Analysts Page.